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ABSTRACT
CD133 has been shown to be an important stem cell factor that promotes glioma 
progression. However, the mechanism for CD133-mediated glioma progression has 
yet to be fully elucidated. In this study, we found that CD133 mRNA expression was 
a prognostic marker in three independent glioma patient cohorts, corroborating a 
putative role for CD133 in glioma progression. Importantly, we found that CD133 
expression in glioma was highly correlated with the expression of HOX gene stem 
cell factors (HOXA5, HOXA7, HOXA10, HOXC4 and HOXC6). The expression of these 
HOX genes individually was significantly associated with survival. Interestingly, 
the prognostic significance of CD133 was dependent on the expression level of HOX 
genes, and vice versa. CD133 (p = 0.021) and HOXA7 (p = 0.001) were independent 
prognostic markers when the three glioma patient cohorts were combined (n = 231). 
Our results suggest that HOX genes may play a more important role in progression 
of glioma when CD133 expression is low. Furthermore, we showed that low-level 
expression of LIM2 in CD133-high glioma was associated with poorer survival, 
suggesting that LIM2 could be a therapeutic target for glioma expressing a high 
level of CD133. Connectivity mapping identified vinblastine and vincristine as agents 
that could reverse the CD133/HOX genes/LIM2-signature, and we confirmed this by  
in vitro analysis in glioma cell lines, demonstrating that CD133 and HOX genes 
were co-expressed and could be downregulated by vincristine. In conclusion, our 
data show that CD133 and HOX genes are important prognostic markers in glioma 
and shed light on possible treatment strategies for glioma expressing a high level 
of CD133.
INTRODUCTION
Glioma is the most common type of primary brain 
tumor. Of the gliomas, grade III astrocytoma and grade IV 
glioblastoma are highly malignant, and afford patients a 
very poor prognosis, with only around 10% surviving for 
more than five years [1, 2]. Increasing evidence indicates 
that stem cell signaling plays an important role in the 
development of gliomas, thereby presenting a potential 
therapeutic target for their treatment [3]. Most importantly, 
glioma stem cells (GSCs) have been shown to be resistant to 
conventional therapies, leading to high treatment failure and 
recurrence in patients with unresectable glioblastoma [4]. 
Several genes and pathways have been linked to GSCs, 
such as Notch, bone morphogenetic proteins, NF-kB, Wnt, 
epidermal growth factor, and Shh [4]. 
Another Two GSC-linked genes are CD133 and nestin; 
CD133, also known as Prominin-1, is a glycoprotein that is 
encoded by the PROM1 gene. Glioblastoma multiforme 
cells grown in neurosphere culture were CD133- and nestin-
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positive and capable of tumor formation in vivo, while 2-D 
cultured counterparts lacked expression and malignancy 
when intracranially implanted in nude mice [5]. CD133 
plays an integral role in cancer progression by maintenance 
of stem cell properties of cancer cells, such as their ability 
to self-renew [6]. CD133 activates the Akt pathway to 
increase cellular resistance to chemotherapy [7], while it also 
promotes cancer cell self-renewal and growth through JNK 
signaling [8]. Prognostic values of CD133 expression have 
been shown in lung cancer [9], gastric cancer [10], colon 
cancer [11], esophageal cancer [12], thyroid cancer [13], 
pancreatic cancer [14] and ovarian cancer [15]. 
Almost a decade ago, a correlation between 
CD133-positivity in glioma specimens and poor 
patient prognosis was reported [16], and its prognostic 
significance in glioma has since been demonstrated in 
two independent meta-analyses [17, 18]. Molecular 
mechanisms of CD133-mediated glioma progression have 
been further revealed recently. CD133 overexpression 
inhibited chemotherapy-induced apoptosis in glioma cell 
lines in vitro [19, 20]. CD133-mediated temozolomide 
resistance in glioma cells was shown to be dependent 
on the activation of Notch and Shh pathways [21], while 
CD133 was shown to confer resistance to multiple 
chemotherapeutic agents via upregulation of CD90, 
CD44, nestin, Msi1 and MELK [20], and the Akt and 
NF-kB pathways [22]. The self-renewing property of 
CD133-positive cells was dependent on the activity of 
Akt [23, 24] and Notch pathways [25], and was enhanced 
in a hypoxic environment via HIF-1a [26]. SirT1, which 
plays an important role in governing the radiosensitivity of 
glioma cells, is a downstream target of CD133 [27]. 
The HOX gene family consists of highly 
conserved hoemodomain transcription factors that, when 
overexpressed, promote glioma initiating potential, poor 
prognosis and chemotherapeutic drug resistance [28]. 
Epigenetic alterations resulted in aberrant expression of 
HOX genes at its transcriptional level [28]. LIM2, lens 
intrinsic membrane protein 2, has been shown to maintain 
cytoskeletal integrity, cell morphology and intercellular 
communication in mouse lenses [29], but little was known 
about the role of LIM2 in cancer or in glioma. 
In this study, we aim to identify genes that are 
co-expressed with CD133 in human glioma specimens, and 
to investigate how these co-expressed genes interact with 
CD133 and influence its prognostic value. Lastly, we aim to 
identify small molecules that could reverse the expression 
of CD133 and its associated genes. 
 RESULTS
The association between CD133 expression and 
survival of patients with glioma 
The association between CD133 expression and 
survival of patients was tested in the three glioma patient 
cohorts with survival data available. In GSE4271 (n = 77; 
Figure 1A), GSE4412 (n = 74; Figure 1B) and GSE7696 
(n = 80; Figure 1C), a high level expression of CD133 in 
the brain tumor was significantly associated with shorter 
survival. Similar results were obtained using Cox-regression 
analysis (Table 1); patients whose brain tumors expressed 
a higher level of CD133 had a significantly higher risk of 
progression or death in GSE4271, GSE4412 and GSE7696. 
When the three cohorts were combined, high-level expression 
of CD133 was significantly associated with a shorter survival 
time (hazard ratio of 1.81, a 95% confidence interval of 
1.33 – 2.45 and a p-value of < 0.001). Patients whose tumors 
expressed a high level of CD133 had a mean survival 
time of 25.7 months compared to 45.7 months for patients 
whose tumors expressed a low-level of CD133 (Figure 1D; 
p < 0.001). The association between high level of CD133 
and shorter survival was observed in patients regardless of 
whether temozolomide was added to radiotherapy as shown 
in Supplementary Figure 1. 
The association between CD133 expression and 
tumor grade
With the exception of GSE7696, all other five brain 
tumor patient datasets included in the current study provided 
information on tumor grade. The association between 
CD133 and tumor grade was tested in the combined cohort 
(with only five cohorts, omitting GSE7696) by Chi-Square 
analysis, and we found a significant correlation between 
CD133 expression and tumor grade (Figure 2; p < 0.001). 
Identification of CD133 co-expressed genes in 
glioma patient datasets
Upon analysis of probeset expression patterns 
in three independent brain tumor patient cohorts 
with survival data available (GSE4271, GSE4412 
and GSE7696) stratified into CD133-high and –low 
subgroups, we found altered expression of several genes 
from the HOX family to be common to all three cohorts. 
HOXA5, HOXA7, HOXA10, HOXC4 and HOXC6 were 
significantly differentially expressed among CD133-high 
and CD133-low tumors in all three independent patient 
cohorts, and were selected for further study. As shown 
in Tables 2A, 2B and 2C, expression of CD133 and the 
five HOX family genes were significantly correlated in 
GSE4271, GSE4412 and GSE7696, respectively. 
The association between the expression of HOX 
genes and survival of patients with glioma
 HOX genes have been shown to play an important 
role in brain malignancies, with multiple HOX genes being 
found to be overexpressed in glioblastoma multiforme, the 
most aggressive glial tumor of the brain [30]. HOXA9 and 
HOXA10 genes were associated with a shorter survival in 
pediatric high-grade glioma patient samples [31], while 
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elevated HOXA9 and HOXA10 gene methylation was 
associated with an increased survival probability [32]. 
We went on to investigate whether the five commonly 
differentially expressed HOX genes were prognostic 
factors in the combined patient cohort for which survival 
data was available. As shown in Figure 3A, patients whose 
tumors expressed a high level of HOXA5 had a mean 
survival time of 26.3 months, compared to 44.9 months 
for those patients whose tumors expressed a low level 
of HOXA5 (Figure 3A; p = 0.001). Similarly, elevated 
HOXA7 (23.7 vs 47.2 months; Figure 3B; p < 0.001), 
HOXA10 (24.1 vs 46.1 months; Figure 3C; p < 0.001), 
HOXC4 (30.4 vs 41.0 months; Figure 3D; p = 0.052) 
and HOXC6 (27.1 vs 44.1 months; Figure 3E; p = 0.002) 
were associated with shorter patient survival. These 
results suggest that the five HOX genes identified to be 
co-expressed with CD133 are also prognostic factors in 
brain tumor patients. 
The prognostic significance of CD133 in patients 
with differential expression of HOX genes
Having determined that CD133 expression is highly 
correlated with the expression of HOX genes, and that 
HOX genes themselves confer prognostic significance 
in brain tumor patients, we went on to further investigate 
the prognostic value of CD133 in brain tumors expressing 
different levels of HOX genes. The mean survival time and 
95% CI for different patterns of expression for different 
genes are listed in Supplementary Table 2.
Figure 1: The association between CD133 and patient survival. Kaplan-Meier analyses for CD133 mRNA expression in 
(A) GSE4271, (B) GSE4412, (C) GSE7696, and (D) the combined cohort.
Table 1: Cox regression analysis for CD133 mRNA in brain tumor cohorts
GSE 4271 GSE 4412 GSE 7696
HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
1.23 1.01–1.50 0.037 1.285 1.00–1.66 0.053 1.34 1.08–1.66 0.007
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Elevated expression of CD133 was significantly 
associated with a shorter survival in patients whose tumors 
expressed HOXA5 at a low level (30.3 vs 50.6 month 
mean survival; Figure 4A; p = 0.006), but there was no 
association between CD133 expression and survival in 
patients whose tumors expressed high levels of HOXA5 
(Figure 4B; p = 0.090). Likewise, CD133 overexpression 
was significantly associated with shorter survival when 
HOXA7 (32.4 vs 53.0 months; Figure 4C; p = 0.003), 
HOXA10 (32.7 vs 52.2 months; Figure 4E; p = 0.008), 
HOXC4 (27.6 vs 47.4 months; Figure 4G; p = 0.003) and 
HOXC6 (29.0 vs 51.0 months; Figure 4I; p = 0.001) were 
lowly expressed. This association was not significant 
or only barely significant when HOXA7 (Figure 4D; 
p = 0.649), HOXA10 (Figure 4F; p = 0.122), HOXC4 
(Figure 4H; p = 0.048) or HOXC6 (Figure 4J; p = 0.166) 
were themselves also overexpressed. The results were 
highly consistent among all the HOX genes identified in 
this study, suggesting that CD133 and HOX genes affect 
the aggressiveness of cancer via similar mechanisms.
Table 2A: GSE4271 brain tumor dataset (n = 100); correlation of CD133 and HOX gene expressions
 CD133 HOXA5 HOXA7 HOXA10 HOXC4 HOXC6
Spearman’s 
rho test
CD133 Correlation Coefficient 1.000 .381** .388** .356** .377** .399**
P value . < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
HOXA5 Correlation Coefficient .381** 1.000 .787** .769** .544** .682**
P value < 0.001 . < 0.001 < 0.001 < 0.001 < 0.001
HOXA7 Correlation Coefficient .388** .787** 1.000 .711** .509** .592**
P value < 0.001 < 0.001 . < 0.001 < 0.001 < 0.001
HOXA10 Correlation Coefficient .356** .769** .711** 1.000 .515** .586**
P value < 0.001 < 0.001 < 0.001 . < 0.001 < 0.001
HOXC4 Correlation Coefficient .377** .544** .509** .515** 1.000 .788**
P value < 0.001 < 0.001 < 0.001 < 0.001 . < 0.001
HOXC6 Correlation Coefficient .339** .682** .592** .586** .788** 1.000
P value. < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 .
**Correlation is significant at the 0.01 level (2-tailed).
*Correlation is significant at the 0.05 level (2-tailed).
Table 2B: GSE4412 brain tumor dataset (n = 85); correlation of CD133 and HOX gene expressions
 CD133 HOXA5 HOXA7 HOXA10 HOXC4 HOXC6
Spearman’s 
rho test
CD133 Correlation Coefficient 1.000 .232* .368** .222* .345** .348**
P value . = 0.032 < 0.001 = 0.041 = 0.001 = 0.001
HOXA5 Correlation Coefficient .232* 1.000 .658** .636** .495** .552**
P value = 0.032 . < 0.001 < 0.001 < 0.001 < 0.001
HOXA7 Correlation Coefficient .368** .658** 1.000 .682** .512** .460**
P value < 0.001 < 0.001 . < 0.001 < 0.001 < 0.001
HOXA10 Correlation Coefficient .222* .636** .682** 1.000 .671** .544**
P value = 0.041 < 0.001 < 0.001 . < 0.001 < 0.001
HOXC4 Correlation Coefficient .345** .495** .512** .671** 1.000 .652**
P value = 0.001 < 0.001 < 0.001 < 0.001 . < 0.001
HOXC6 Correlation Coefficient .348** .552** .460** .544** .652** 1.000
P value. = 0.001 < 0.001 < 0.001 < 0.001 < 0.001 .
**Correlation is significant at the 0.01 level (2-tailed).
*Correlation is significant at the 0.05 level (2-tailed).
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The prognostic significance of HOX genes in 
patients with differential expression of CD133
Having demonstrated that HOX genes had 
prognostic potential in brain tumor patients, we went on to 
analyze whether the prognostic significance of HOX genes 
was affected by CD133 expression. Here, we present the 
data from Figure 4 in a different configuration in Figure 5 
to illustrate the prognostic significance of HOX genes 
in specimens with different CD133 expression levels. 
Overexpression of HOX5A was predictive of a shorter 
survival in the CD133-low subgroup (33.1 vs 50.6 months 
mean survival; Figure 5A; p = 0.042), but not in the 
CD133 overexpressing subgroup (Figure 5B; p = 0.291). 
HOXA7 was predictive of survival in CD133-low (29.4 vs. 
53.0 months; Figure 5C; p < 0.001), but not in CD133-
high tumors (Figure 5D; p = 0.133). HOXA10 was 
similarly predictive of survival in CD133-low (32.2 vs. 
52.2 months; Figure 5E; p = 0.006), but not in CD133-high 
tumors (Figure 5F; p = 0.058), as was HOXC6 predictive 
of survival in CD133-low (33.4 vs 51.0 months; Figure 5I; 
p = 0.022), but not in CD133-high tumors (Figure 5J; 
p = 0.366). Interestingly, HOXC4 expression was not 
predictive of survival in either CD133-low (Figure 5G; 
p = 0.313) or CD133-high (Figure 5H; p = 0.845) 
subgroups of patients. These results suggest that HOX 
Table 2C: GSE7696 brain tumor dataset (n = 84); correlation of CD133 and HOX gene expressions
 CD133 HOXA5 HOXA7 HOXA10 HOXC4 HOXC6
Spearman’s 
rho test
CD133 Correlation Coefficient 1.000 .398* .410** .280** .308** .337**
P value . = 0.032 < 0.001 = 0.01 = 0.004 = 0.002
HOXA5 Correlation Coefficient .398* 1.000 .710** .694** .582** .660**
P value = 0.032 . < 0.001 < 0.001 < 0.001 < 0.001
HOXA7 Correlation Coefficient .410** .710** 1.000 .773** .492** .518**
P value < 0.001 < 0.001 . < 0.001 < 0.001 < 0.001
HOXA10 Correlation Coefficient .280** .694** .773** 1.000 .535** .590**
P value = 0.01 < 0.001 < 0.001 . < 0.001 < 0.001
HOXC4 Correlation Coefficient .308** .582** .492** .535** 1.000 .623**
P value = 0.004 < 0.001 < 0.001 < 0.001 . < 0.001
HOXC6 Correlation Coefficient .337** .660** .518** .590** .623** 1.000
P value. = 0.002 < 0.001 < 0.001 < 0.001 < 0.001 .
**Correlation is significant at the 0.01 level (2-tailed).
*Correlation is significant at the 0.05 level (2-tailed).
Figure 2: The association between CD133 mRNA expression and tumor grade. A histogram displaying the association 
between CD133 mRNA expression profile and tumor grading in the combined cohort.
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genes may play a more important role in enhancing the 
aggressiveness of brain tumors with a low level expression 
of CD133. 
CD133 and HOXA7 genes are independent 
prognostic factors in brain malignancies
Multivariate Cox regression was performed to 
investigate whether CD133 expression and the expression 
of HOX genes identified in this study are independent 
prognostic factors. As shown in Table 3, by a forward 
stepwise approach with an entry limit of p < 0.05, only 
CD133 expression (p = 0.021) and HOXA7 expression 
(p = 0.001) were independent prognostic markers in brain 
tumor patients.
Identification of genes that predict survival in 
patients with tumors expressing a high level of 
CD133
Since a high level of CD133 was associated with 
a shorter survival in brain tumor patients, we sought to 
identify additional genes that could be used to further 
augment the predictive power of CD133, or to identify 
potential therapeutic targets for this group of patients 
with poor prognosis. By comparing CD133-high patients 
who were still alive and those who were deceased at 
data collection, we found that LIM2 expression was 
significantly differentially expressed. We went on to 
further investigate the prognostic significance of LIM2, 
and found that a low level of LIM2 was significantly 
correlated with a shorter survival time in patients with 
brain tumors (Figure 6A; p = 0.005). LIM2-low patients 
had a mean survival time of 25.3 months while LIM2-
high patients had a mean survival time of 43.1 months. 
Expression of CD133 was significantly associated with 
survival in both LIM2-low (Figure 6B; p = 0.005) and 
LIM2-high (Figure 6C; p = 0.017) patients. However, in 
a different configuration, the association between LIM2 
and survival was only observed in CD133-high patients 
(Figure 6E; p = 0.040), but not in CD133-low patients 
(Figure 6D; p = 0.155). Importantly, CD133 expression 
and LIM2 expression were independent prognostic 
markers in brain tumor patients as shown by multivariate 
Cox regression analysis (Table 4). 
The association between CD133, VEGFa and 
survival
We have previously shown that VEGFa is a 
prognostic marker in brain tumor patients [33]. In the 
present study, we found that CD133 expression was 
associated with survival. Interestingly, we further found 
that CD133 expression was significantly higher in VEGFa-
high patients than in VEGFa-low patients (Figure 7A; 
p = 0.049), although CD133 was significantly associated 
with survival only in VEGFa-low patients (Figure 7B; 
p = 0.002) but not in VEGFa-high patients (Figure 7C; 
Figure 3: The association between mRNA expression of HOX genes and survival. Kaplan-Meier analyses for (A) HOXA5, 
(B) HOXA7, (C) HOXA10, (D) HOXC4 and (E) HOXC6 mRNA expression in the combined cohort.
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p = 0.091). On the other hand, VEGFa expression was 
significantly associated with survival in both CD133-low 
patients (Figure 7D; p = 0.002) and CD133-high patients 
(Figure 7E; p = 0.047). Importantly, multivariate Cox 
regression analysis showed that VEGFa expression and 
CD133 expression were independent prognostic markers 
in patients with brain tumors (Table 5). 
Identification of small molecules that could 
reverse the expression of CD133/HOX genes/
LIM2-signature
Having shown that overexpression of CD133 and 
HOX genes and suppression of LIM2 were markers of 
poor prognosis, we used connectivity mapping to identify 
molecules that could reverse the expression of these genes. 
In the analysis, we found that the three chemotherapeutic 
agents most likely to reverse the gene expression profile 
identified were vinblastine (p < 0.001), vincristine 
(p < 0.001) and epirubicin (p < 0.001).
The expression of CD133 and HOX genes in 
glioma cell lines
mRNA expression of CD133 and HOX genes 
was tested in two glioma cell lines, U251 and U87. We 
found that CD133 (Figure 8A), HOXA5 (Figure 8B), 
HOXA7 (Figure 8C), HOXC4 (Figure 8D) and HOXC6 
(Figure 8E) were significantly higher in U251 cells then 
in U87 cells (P < 0.001; Figure 8). This result supports 
our analysis in human glioma patient cohorts in which 
these genes are significantly correlated with each other. 
HOXA10 mRNA was not detected in U87 or in U251 
cells. Importantly, we also confirmed the results of 
connectivity mapping, whereby treatment of U251 and 
U87 cells with vincristine for 24 hours downregulated the 
expression of CD133 (Figure 8A), HOXA5 (Figure 8B), 
HOXA7 (Figure 8C), HOXC4 (Figure 8D) and HOXC6 
(Figure 8E). Furthermore, we found that U251 cells, which 
express higher level of CD133 and HOX genes were more 
sensitive to vincristine treatment than U87 cells in terms 
of cell viability (Figure 8F) and cell apoptosis (Figure 8G). 
These results suggest that CD133 and HOX genes can be 
downregulated by vincristine, and that a higher expression 
of these genes may be a predictive marker for vincristine 
sensitivity.
DISCUSSION
In the present study, we demonstrated that CD133 
overexpression predicts poor prognosis in patients with 
glioma. Importantly, for the first time, we showed that 
CD133 expression was highly correlated with expression 
of several HOX genes. These HOX genes are themselves 
prognostic markers in glioma, while the prognostic value 
for CD133 and HOX genes are mostly interdependent, 
with the exception of HOXA7. Moreover, we have 
identified that analysis of LIM2 expression could be 
used to further augment the prognostication of patients 
in the at-risk CD133-high subgroup. CD133 was also 
associated with VEGFa expression, suggesting a possible 
role of CD133 in promoting angiogenesis. Further analysis 
suggests that several chemotherapeutic agents may reverse 
the expression of CD133 and HOX genes.
An expression signature dominated by HOX genes 
and CD133 was a predictor for poor survival in glioma 
patients treated with concomitant chemoradiotherapy [34], 
suggesting that these genes may interact with one 
another. Multiple HOX genes have been shown to 
be overexpressed in glioma and confer prognostic 
value [30, 35], while HOXA10 has been shown to play a 
role in drug resistance and tumor recurrence [36]. In the 
present study, we found that HOXA5, HOXA7, HOXA10, 
HOXC4 and HOXC6 are prognostic markers in glioma 
patients. Interestingly, CD133 expression only confers 
prognostic value in patients expressing a low level of 
HOX genes, while expression of HOX genes confers 
prognostic value in patients expressing a low level of 
CD133, suggesting that the overexpression of either 
CD133 or HOX genes may be sufficient to drive glioma 
progression, while overexpression of both of CD133 and 
HOX genes may only slightly further enhance progression 
potential. Importantly, we found that CD133 and HOXA7 
expressions were independent factors for predicting 
patient survival, suggesting that HOXA7 expression could 
add further value to the prognostic significance of CD133 
expression. In view of this, CD133 or CD133 and HOX 
genes should be tested in clinical trial to evaluate whether 
Table 3: Multivariate Cox-regression analysis for HOX genes and CD133
Factor Hazard Ratio 95% Confidence Interval P-value for inclusion
CD133 1.467 1.059–2.032 0.021
HOXA5 NS NS 0.748
HOXA7 1.767 1.277–2.446 0.001
HOXA10 NS NS 0.155
HOXC4 NS NS 0.526
HOXC6 NS NS 0.315
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Figure 4: The association between CD133 mRNA expression and survival in glioma patients with different level of 
expression of HOX genes. Kaplan-Meier analyses for CD133 mRNA expression in the combined cohort of glioma patients expressing 
(A) a low level of HOXA5, (B) a high level of HOXA5, (C) a low level of HOXA7, (D) a high level of HOXA7, (E) a low level of 
HOXA10, (F) a high level of HOXA10, (G) a low level of HOXC4, (H) a high level of HOXC4, (I) a low level of HOXC6, and (J) a high 
level of HOXC6.
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Figure 5: The association between mRNA expression of HOX genes and survival in glioma patients with different level 
of expression of CD133. Kaplan-Meier analyses for HOXA5 expression in (A) CD133-low and (B) CD133-high glioma, for HOXA7 
expression in (C) CD133-low and (D) CD133-high glioma, for HOXA10 expression in (E) CD133-low and (F) CD133-high glioma, for 
HOXC4 expression in (G) CD133-low and (H) CD133-high glioma, and for HOXC6 expression in (I) CD133-low and (J) CD133-high 
glioma in the combined cohort.
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the novel intervention could be effective specifically in 
this subgroup of glioma patients. 
We have also identified LIM2 as a factor that could 
further predict survival in patients with CD133-high glioma. 
Little is known about the LIM2 gene. A comparative analysis 
of wild-type and LIM2-deficient mice revealed that LIM2 
may have a role in maintaining cytoskeletal integrity, cell 
morphology and intercellular communication within lenses 
[29]. However, to the best of our knowledge, there seems to 
be no prior evidence implicating an involvement of LIM2 
in cancer. On the other hand, there is evidence regarding 
the involvement of LIM2 in human brain development [37], 
so it is conceivable that dysregulation of LIM2 expression 
could manifest a malignant phenotype in brain cells. 
Further investigations are required to understand how LIM2 
interacts with CD133 in glioma progression.
Several chemotherapeutic agents, namely vinblastine, 
vincristine, and epirubicin, were identified through 
connectivity mapping for their effect in reversing the 
CD133/HOX genes/LIM2 poor prognostic signature. 
Vinblastine has activity in pediatric low-grade gliomas [38]. 
However, its activity in adult human gliomas has not been 
studied. Vincristine has been shown to be effective in 
treating gliomas [39] and is one of the chemotherapeutic 
agents in a standard regimen (procarbazine, lomustine 
and vincristine) for the treatment of low-grade gliomas 
Table 4: Multivariate Cox-regression analysis for LIM2 and CD133
Factor Hazard Ratio 95% Confidence Interval P-value for inclusion
CD133 1.759 1.296–2.388 < 0.001
LIM2 0.679 0.502–0.919 0.012
Table 5: Multivariate Cox-regression analysis for VEGFa and CD133
Factor Hazard Ratio 95% Confidence Interval P-value for inclusion
CD133 1.611 1.197 – 2.170 0.002
VEGFa 1.692 1.257 – 2.277 0.001
Figure 6: The association between LIM2 mRNA expression and survival. (A) Kaplan-Meier analysis for LIM2 mRNA 
expression in the combined glioma patient cohort. Kaplan-Meier analyses for CD133 mRNA expression in patients with (B) a low level 
expression of LIM2 and (C) a high level expression of LIM2. Kaplan-Meier analyses for LIM2 mRNA expression in patients with (D) a 
low level expression of CD133 and (E) a high level expression of CD133.
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requiring postsurgical adjuvant chemotherapy [40]. In 
high-grade gliomas, vincristine in combination with 
procarbazine and lomustine was found to be comparable 
to temozolomide in terms of efficacy endpoints [41]. 
Since both vinblastine and vincristine are alkaloid-type 
chemotherapeutic agents that target microtubule dynamics 
through binding to tubulin, it is surprising that connectivity 
mapping suggested that they might regulate CD133, HOX 
genes and LIM2. Epirubicin acts through effects on DNA. 
It was encouraging that our in vitro analysis of cellular 
response to vincristine treatment supported our clinical 
cohort data, whereby the cells rich in the identified 
markers (U251) were significantly more susceptible to 
the cytotoxic properties of vincristine than the cells that 
expressed those markers at a relatively lower level (U87). 
It would be interesting to confirm this finding in clinical 
trials with CD133 as biomarker for patient stratification on 
which chemotherapeutic agents should be given.  
Patients with glioma, in general, have poor 
prognosis compared to other types of solid tumors. In 
the present study, we have identified that a subgroup of 
patients with high level expression of CD133 and HOX 
genes had even worse prognosis than those with different 
expression patterns, suggesting the ineffectiveness of 
current treatment modalities to these patients. Whether 
reversing expression of these genes could be a novel 
therapeutic approach to prolong survival for this group of 
patients requires further investigation.
MATERIALS AND METHODS
Extraction of clinical and microarray gene 
expression data from glioma patient datasets 
Three glioma patient datasets, GSE4271 [42], 
GSE4412 [43] and GSE7696 [34] were identified in the Gene 
Expression Omnibus (GEO) Database; datasets compiled 
using the HG-U133 microarray platform, and comprising 
> 70 patients for whom survival data were available, were 
included in this study. The patient characteristics for these 
three datasets are listed in Supplementary Table 1. Three 
other glioma patient datasets, GSE4290 [44], GSE16011 [45] 
and GSE52009, all of which comprise stage and expression 
data, were also included. Microarray gene expression data 
were retrieved from the data matrixes deposited to the GEO 
database by the original authors. R scripting was used to 
extract the expression values from probesets of CD133, 
HOXA5, HOXA7, HOXA10, HOXC4, HOXC6 and LIM2, 
and the clinical data from the data matrixes downloaded 
from GEO as previously described [46]. 
Patient stratification
Expression levels were divided into four groups 
using quartile as the cut-off points. Expression levels were 
further divided into high and low levels using median 
expression level as the cut-off point for survival analysis. 
Figure 7: The association between VEGFa mRNA expression, CD133 mRNA expression and survival. (A) A histogram 
showing the association between the expression levels of VEGFa and CD133. Kaplan-Meier analyses for CD133 mRNA expression in 
patients with (B) a low level expression of VEGFa and (C) a high level expression of VEGFa. Kaplan-Meier analyses for VEGFa mRNA 
expression in patients with (D) a low level expression of CD133 and (E) a high level expression of CD133.
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Correlations of gene expression levels and 
clinical data
All statistical analyses were performed using 
SPSS19.0. For Kaplan-Meier survival analysis, results 
were compared by log-rank test. Univariate Cox regression 
analysis was used to correlate the gene expression levels 
and patient survival, while multivariate Cox regression 
analysis was used to identify independent prognostic 
factors using a forward stepwise approach with a p value 
of 0.05 for inclusion. The three datasets with survival 
status available were combined into one to increase the 
sample size for detailed analysis. The associations between 
expression levels of genes were tested by Spearman’s 
rank test. The association between tumor grade and gene 
expression was tested by Chi-Square test.
Identification of genes co-expressed with CD133
The gene expression patterns of patients in the CD133-
high and CD133-low subgroups were compared. Probesets 
that were differentially expressed between these two subgroups 
were identified by 2-sample Welch’s T-test, avoiding the type 
I error due to unequal variances of the values of probesets 
between these two subgroups. Briefly, a Welch’s t test was 
applied to each probeset corresponding to a particular gene 
in the data matrix using our own Java application, MyStats. P 
values and the differential expression in fold changes for all the 
probesets were generated as tab-delimited Excel worksheets 
for further analysis. Genes found to be co-expressed 
with CD133 were ranked by ascending p-values. The genes 
found to be co-expressed with CD133 that were common to 
all three patient datasets were analyzed further.
Figure 8: Expression of CD133 and HOX genes in human glioblastoma cell lines treated with vincristine. (A) A histogram 
showing the relative expression of CD133 in control and vincristine treated U87 and U251 cells. (B) A histogram showing the relative 
expression of HOXA5 in control and vincristine treated U87 and U251 cells. (C) A histogram showing the relative expression of HOXA7 
in control and vincristine treated U87 and U251 cells. (D) A histogram showing the relative expression of HOXC4 in control and vincristine 
treated U87 and U251 cells. (E) A histogram showing the relative expression of HOXC6 in control and vincristine treated U87 and U251 
cells. (F) The percentage of cell viability of U87 and U251 cells treated with different concentration of vincristine determined by MTT 
assay. (G) The percentage of apoptotic cells in control and vincristine treated U87 and U251 cells as determined by Annexin V and PI 
staining through flow cytometry. Each data point with standard deviation represents three biological replicates. 
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Identification of gene target for patients with 
brain tumors overexpressing CD133
Patients who overexpressed CD133 were stratified 
into two groups based on mortality. Differential expressions 
of different probesets between patients in the CD133-high-
alive subgroup and those in the CD133-high-deceased 
subgroup were identified as described above.
Identification of potential inhibitory compounds 
targeting CD133/HOX genes/LIM2 glioma 
(Connectivity Map)
Gene expression connectivity mapping was 
performed using Statistically Significant Connection’s 
Map (sscMap) to identify candidate small molecule 
compounds that may reverse the overexpression of CD133 
and HOX genes and suppression of LIM2 gene [47–49]. 
The CD133/HOX genes/LIM2 probes were input to the 
Java application sscMap [49] as a query signature, and 
its association with the 6000 gene expression profiles 
generated by treating cancer cells with over 1000 small 
molecules were compared. The gene signature perturbation 
procedure, which increases the specificity of the output 
results, was applied as previously described [50]. All 
the small molecular compounds that were negatively 
associated with the input were sorted and ranked by their 
p-value, perturbation stability and standardized connection 
score. The p-value that was considered significant was set 
at a stringent threshold (p = 1/1309), ensuring that the 
results generated by sccMap would yield a maximum of 
one false positive small molecule over the 1309 small 
molecules tested in the sccMap [50]. 
Cell culture
Two glioma cell lines, namely U87MG and U251 
were used for the in vitro assays. U87MG and U251 were 
obtained from ATCC. They were cultured in Dulbecco’s 
Modified Eagle’s medium (Life Technologies) with 10% 
fetal bovine serum (FBS, Gibco, Life Technologies) and 
1% penicillin/streptomycin (Gibco, Life Technologies). 
Cell cultures were maintained in a 37°C incubator with 
5% CO2 and 95% air.
RNA extraction and reverse transcription 
polymerase chain reaction (RT-PCR)
Cells were grown in a 6-well cell culture dish at 
a density of 2.5 × 106 cells per well for 24 hour. RNA 
extraction was performed using RNeasy® Mini Kit 
(QIAGEN) according to the manufacturer’s instructions. 
Cells were disrupted by addition of lysis buffer, and the 
lysate was then put into a QIAshredder spin column for 
purification. RNA was eluted in the RNase-free water.
1 μg RNA was reverse transcribed into cDNA 
using High Capacity cDNA Reverse Transcription Kit 
(Thermo Fisher Scientific) according to the manufacturer’s 
instructions. Each reverse transcription mix consisted of 
RT Buffer, dNTP Mix, RT Random Primers, MultiScribeTM 
Reverse Transcriptase, nuclease-free H
2
O and RNA 
samples. RT-PCR was carried out in a C1000 TouchTM 
Thermal Cycler (Bio-Rad) following the recommended 
thermal cycle program (25°C for 10 min, 37°C for 
120 min, and 85°C for 5 min). cDNA products were stored 
in –80°C prior to use.
Qualitative-PCR analysis of CD133 and HOX 
genes in glioma cell lines
QPCR reactions were carried out by mixing 5 μl 
TaqMan® Universal PCR Master Mix (Thermo Fisher 
Scientific), 4 μl H2O and 1 μl cDNA sample. QPCR 
was conducted in a Mx3000P qPCR System (Agilent), 
with the following thermal cycling program: 95°C for 
10 min, 40 cycles at 95°C for 15 sec and 60°C for 1 min. 
GAPDH was regarded as the reference gene, and relative 
abundance was calculated using the comparative Ct 
(2−ΔΔCt) method. Taqman qPCR probes were obtained from 
Thermo Fisher Scientific; CD133 (Hs01009257_m1), 
HOXA5 (Hs00430330_m1), HOXA7 (Hs00600844_m1), 
HOXA10 (Hs00172012_m1), HOXC4 (Hs00538088_m1) 
and HOXC6 (Hs00171690_m1); all probes spanned exons, 
preventing amplification of genomic DNA, and all probes 
had a PCR efficiency of 100% (± 10%) (https://www.
thermofisher.com/hk/en/home/life-science/pcr/real-time-
pcr/real-time-pcr-assays/why-choose-taqman-assays.html). 
The QPCR experiments were repeated three times for each 
batch of RNA, and three batches of RNA were extracted 
from three independent cell culture experiments. 
Cell viability and cell apoptosis upon Drug 
Treatment
Glioma cell lines were seeded at a density of 3000 per 
well in a 96-well plate (for MTT assay) and 3 × 105 per 
well in a 6-well plate (for apoptosis assay) and were 
allowed to grow for 24 hours. Vincristine sulfate was 
added to the culture medium and the cells were harvested 
24 hours post-treatment. Cell viability was measured by 
MTT assay, while cell apoptosis was measured by Alexa 
Fluor 488 Annexin V/Dead Cell Apoptosis Kit (Invitrogen) 
by flow cytometry.
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